CSL Vifor Overview
- Year Founded
-
1871
- Status
-
Acquired/Merged
- Employees
-
2,600
- Latest Deal Type
-
M&A
- Financing Rounds
-
7
- Investments
-
32
CSL Vifor General Information
Description
Operator of a specialty drug manufacturing and licensing company focused on iron deficiency and kidney diseases. The company specializes in global strategic collaboration, licensing, and the development, manufacturing, and commercialization of precision healthcare pharmaceuticals to help patients worldwide lead better, healthier lives.
Contact Information
Website
www.cslvifor.es(Operating Subsidiary)
Corporate Office
- Flughofstrasse 61
- P.O. Box
- 8152 Glattbrugg
- Switzerland
Corporate Office
- Flughofstrasse 61
- P.O. Box
- 8152 Glattbrugg
- Switzerland
CSL Vifor Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CSL Vifor Comparisons
Industry
Financing
Details
CSL Vifor Competitors (32)
One of CSL Vifor’s 32 competitors is Sun Pharmaceutical Industries, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Corporation | Mumbai, India | ||||
| Zydus Lifesciences | Corporation | Ahmedabad, India | ||||
| Dr. Reddy's | Corporation | Hyderabad, India | ||||
| Cipla | Corporation | Mumbai, India | ||||
| GSK | Corporation | London, United Kingdom |
CSL Vifor Patents
CSL Vifor Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026120158-A1 | Process for reducing no-impurities (ndsris) in solid dosage forms of ferroportin inhibitors | Pending | 06-Dec-2024 | ||
| WO-2026120150-A1 | Prolonged-release dosage forms of ferroportin inhibitors | Pending | 06-Dec-2024 | ||
| WO-2026120152-A1 | Prolonged-release dosage forms of ferroportin inhibitors for use in treating hereditary haemochromatosis | Pending | 06-Dec-2024 | ||
| WO-2026041650-A1 | Ferroportin-inhibitors for the use in the treatment of lupus nephritis | Pending | 20-Aug-2024 | ||
| EP-4828610-A1 | Novel synthesis of methyl-2-fluoroacrylate | Pending | 21-Dec-2023 | C07C67/08 |
CSL Vifor Signals
CSL Vifor Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CSL Vifor Investments & Acquisitions (32)
CSL Vifor’s most recent deal was a Merger/Acquisition with Inositec for . The deal was made on 30-Nov-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Inositec | 30-Nov-2021 | Merger/Acquisition | Drug Discovery | ||
| Sanifit | 22-Nov-2021 | Merger/Acquisition | Drug Discovery | ||
| Angion Biomedica | 09-Feb-2021 | PIPE | Drug Discovery | ||
| Cara Therapeutics | 15-Oct-2020 | PIPE | Drug Discovery | ||
| Weifu Fresenius Kabi | 29-May-2020 | Joint Venture | Consulting Services (B2B) |
CSL Vifor Exits (7)
CSL Vifor’s most recent exit was on 15-Oct-2020 from Cara Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cara Therapeutics | 15-Oct-2020 | Completed |
|
||
| NephThera | 06-Nov-2019 | Completed |
|
||
| Akebia Therapeutics | 15-May-2017 | Completed |
|
||
| Chemocentryx | 11-May-2016 | Completed |
|
||
| OM Pharma | 08-Sep-2009 | Merger/Acquisition | Completed |
CSL Vifor Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Renapharma | Stockholm, Sweden | 2000 | |
| Sun Store | Bern, Switzerland | 1972 | |
| Perskindol | Switzerland | 1954 | |
| Galenica Personalvorsorgestiftung | Bern, Switzerland | 1940 | |
| Galexis | Niederbipp, Switzerland |
CSL Vifor FAQs
-
When was CSL Vifor founded?
CSL Vifor was founded in 1871.
-
Where is CSL Vifor headquartered?
CSL Vifor is headquartered in Glattbrugg, Switzerland.
-
What is the size of CSL Vifor?
CSL Vifor has 2,600 total employees.
-
What industry is CSL Vifor in?
CSL Vifor’s primary industry is Pharmaceuticals.
-
Is CSL Vifor a private or public company?
CSL Vifor is a Private company.
-
What is the current valuation of CSL Vifor?
The current valuation of CSL Vifor is .
-
What is CSL Vifor’s current revenue?
The current revenue for CSL Vifor is .
-
How much funding has CSL Vifor raised over time?
CSL Vifor has raised $103M.
-
Who are CSL Vifor’s investors?
Alliance Healthcare, Ally Bridge Group, Kohlberg Kravis Roberts, and Priora have invested in CSL Vifor.
-
Who are CSL Vifor’s competitors?
Sun Pharmaceutical Industries, Zydus Lifesciences, Dr. Reddy's, Cipla, and GSK are some of the 32 competitors of CSL Vifor.
-
When was CSL Vifor acquired?
CSL Vifor was acquired on 09-Aug-2022.
-
Who acquired CSL Vifor?
CSL Vifor was acquired by CSL.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process